nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylergometrine—Cramps of lower extremities—Tamoxifen—pancreatic cancer	0.00787	0.0216	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Erlotinib—pancreatic cancer	0.00628	0.0172	CcSEcCtD
Methylergometrine—Nasal congestion—Sunitinib—pancreatic cancer	0.00585	0.016	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Sunitinib—pancreatic cancer	0.00544	0.0149	CcSEcCtD
Methylergometrine—Angina pectoris—Tamoxifen—pancreatic cancer	0.00524	0.0143	CcSEcCtD
Methylergometrine—Thrombophlebitis—Irinotecan—pancreatic cancer	0.00507	0.0139	CcSEcCtD
Methylergometrine—Thrombophlebitis—Fluorouracil—pancreatic cancer	0.00486	0.0133	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Irinotecan—pancreatic cancer	0.00448	0.0123	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Gemcitabine—pancreatic cancer	0.00436	0.0119	CcSEcCtD
Methylergometrine—Bradycardia—Sunitinib—pancreatic cancer	0.00375	0.0103	CcSEcCtD
Methylergometrine—Angina pectoris—Irinotecan—pancreatic cancer	0.00369	0.0101	CcSEcCtD
Methylergometrine—Sweating increased—Irinotecan—pancreatic cancer	0.00369	0.0101	CcSEcCtD
Methylergometrine—Muscle spasms—Tamoxifen—pancreatic cancer	0.0036	0.00986	CcSEcCtD
Methylergometrine—Angina pectoris—Fluorouracil—pancreatic cancer	0.00354	0.00969	CcSEcCtD
Methylergometrine—Thrombophlebitis—Docetaxel—pancreatic cancer	0.0035	0.0096	CcSEcCtD
Methylergometrine—Cardiac disorder—Sunitinib—pancreatic cancer	0.00342	0.00937	CcSEcCtD
Methylergometrine—Hypertension—Tamoxifen—pancreatic cancer	0.00323	0.00886	CcSEcCtD
Methylergometrine—Chest pain—Tamoxifen—pancreatic cancer	0.00319	0.00873	CcSEcCtD
Methylergometrine—Chest pain—Erlotinib—pancreatic cancer	0.00316	0.00864	CcSEcCtD
Methylergometrine—Haematuria—Gemcitabine—pancreatic cancer	0.00314	0.0086	CcSEcCtD
Methylergometrine—Bradycardia—Irinotecan—pancreatic cancer	0.00309	0.00846	CcSEcCtD
Methylergometrine—Muscle spasms—Sunitinib—pancreatic cancer	0.00308	0.00845	CcSEcCtD
Methylergometrine—Nervous system disorder—Erlotinib—pancreatic cancer	0.00297	0.00812	CcSEcCtD
Methylergometrine—Hyperhidrosis—Tamoxifen—pancreatic cancer	0.00296	0.00809	CcSEcCtD
Methylergometrine—Atrioventricular block—Epirubicin—pancreatic cancer	0.00291	0.00796	CcSEcCtD
Methylergometrine—Ventricular tachycardia—Epirubicin—pancreatic cancer	0.00282	0.00772	CcSEcCtD
Methylergometrine—Cardiac disorder—Irinotecan—pancreatic cancer	0.00282	0.00772	CcSEcCtD
Methylergometrine—Convulsion—Sunitinib—pancreatic cancer	0.00278	0.00761	CcSEcCtD
Methylergometrine—Hypertension—Sunitinib—pancreatic cancer	0.00277	0.00759	CcSEcCtD
Methylergometrine—Paraesthesia—Tamoxifen—pancreatic cancer	0.00275	0.00752	CcSEcCtD
Methylergometrine—Cardiac disorder—Gemcitabine—pancreatic cancer	0.00274	0.00752	CcSEcCtD
Methylergometrine—Chest pain—Sunitinib—pancreatic cancer	0.00273	0.00748	CcSEcCtD
Methylergometrine—Dyspnoea—Tamoxifen—pancreatic cancer	0.00273	0.00746	CcSEcCtD
Methylergometrine—Dyspnoea—Erlotinib—pancreatic cancer	0.0027	0.00738	CcSEcCtD
Methylergometrine—Atrioventricular block—Doxorubicin—pancreatic cancer	0.00269	0.00736	CcSEcCtD
Methylergometrine—Ventricular tachycardia—Doxorubicin—pancreatic cancer	0.00261	0.00714	CcSEcCtD
Methylergometrine—Cramps of lower extremities—Epirubicin—pancreatic cancer	0.00259	0.00709	CcSEcCtD
Methylergometrine—Nervous system disorder—Sunitinib—pancreatic cancer	0.00257	0.00703	CcSEcCtD
Methylergometrine—Angina pectoris—Docetaxel—pancreatic cancer	0.00255	0.00699	CcSEcCtD
Methylergometrine—Muscle spasms—Irinotecan—pancreatic cancer	0.00254	0.00696	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.0025	0.00685	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.00247	0.00677	CcSEcCtD
Methylergometrine—Abdominal pain—Tamoxifen—pancreatic cancer	0.00242	0.00662	CcSEcCtD
Methylergometrine—Cramps of lower extremities—Doxorubicin—pancreatic cancer	0.0024	0.00656	CcSEcCtD
Methylergometrine—Abdominal pain—Erlotinib—pancreatic cancer	0.00239	0.00655	CcSEcCtD
Methylergometrine—Thrombophlebitis—Epirubicin—pancreatic cancer	0.00236	0.00647	CcSEcCtD
Methylergometrine—Paraesthesia—Sunitinib—pancreatic cancer	0.00235	0.00644	CcSEcCtD
Methylergometrine—Dyspnoea—Sunitinib—pancreatic cancer	0.00233	0.00639	CcSEcCtD
Methylergometrine—Hypertension—Irinotecan—pancreatic cancer	0.00228	0.00625	CcSEcCtD
Methylergometrine—Hypertension—Gemcitabine—pancreatic cancer	0.00222	0.00609	CcSEcCtD
Methylergometrine—Convulsion—Fluorouracil—pancreatic cancer	0.00219	0.00601	CcSEcCtD
Methylergometrine—Chest pain—Gemcitabine—pancreatic cancer	0.00219	0.006	CcSEcCtD
Methylergometrine—Thrombophlebitis—Doxorubicin—pancreatic cancer	0.00219	0.00599	CcSEcCtD
Methylergometrine—Anaphylactic shock—Irinotecan—pancreatic cancer	0.00216	0.00591	CcSEcCtD
Methylergometrine—Chest pain—Fluorouracil—pancreatic cancer	0.00216	0.0059	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.00214	0.00586	CcSEcCtD
Methylergometrine—Nervous system disorder—Irinotecan—pancreatic cancer	0.00212	0.00579	CcSEcCtD
Methylergometrine—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.0021	0.00575	CcSEcCtD
Methylergometrine—Diarrhoea—Tamoxifen—pancreatic cancer	0.00209	0.00573	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Epirubicin—pancreatic cancer	0.00209	0.00572	CcSEcCtD
Methylergometrine—Hyperhidrosis—Irinotecan—pancreatic cancer	0.00209	0.00571	CcSEcCtD
Methylergometrine—Abdominal pain—Sunitinib—pancreatic cancer	0.00207	0.00567	CcSEcCtD
Methylergometrine—Diarrhoea—Erlotinib—pancreatic cancer	0.00207	0.00567	CcSEcCtD
Methylergometrine—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.00207	0.00566	CcSEcCtD
Methylergometrine—Nervous system disorder—Gemcitabine—pancreatic cancer	0.00206	0.00564	CcSEcCtD
Methylergometrine—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.00203	0.00556	CcSEcCtD
Methylergometrine—Nervous system disorder—Fluorouracil—pancreatic cancer	0.00203	0.00555	CcSEcCtD
Methylergometrine—Dizziness—Tamoxifen—pancreatic cancer	0.00202	0.00554	CcSEcCtD
Methylergometrine—Tachycardia—Fluorouracil—pancreatic cancer	0.00202	0.00552	CcSEcCtD
Methylergometrine—Hypotension—Irinotecan—pancreatic cancer	0.00202	0.00552	CcSEcCtD
Methylergometrine—Dizziness—Erlotinib—pancreatic cancer	0.002	0.00548	CcSEcCtD
Methylergometrine—Hypotension—Gemcitabine—pancreatic cancer	0.00196	0.00538	CcSEcCtD
Methylergometrine—Cardiac disorder—Docetaxel—pancreatic cancer	0.00195	0.00533	CcSEcCtD
Methylergometrine—Vomiting—Tamoxifen—pancreatic cancer	0.00194	0.00532	CcSEcCtD
Methylergometrine—Paraesthesia—Irinotecan—pancreatic cancer	0.00194	0.0053	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Doxorubicin—pancreatic cancer	0.00193	0.00529	CcSEcCtD
Methylergometrine—Hypotension—Fluorouracil—pancreatic cancer	0.00193	0.00529	CcSEcCtD
Methylergometrine—Rash—Tamoxifen—pancreatic cancer	0.00193	0.00528	CcSEcCtD
Methylergometrine—Dermatitis—Tamoxifen—pancreatic cancer	0.00193	0.00527	CcSEcCtD
Methylergometrine—Vomiting—Erlotinib—pancreatic cancer	0.00192	0.00527	CcSEcCtD
Methylergometrine—Dyspnoea—Irinotecan—pancreatic cancer	0.00192	0.00527	CcSEcCtD
Methylergometrine—Headache—Tamoxifen—pancreatic cancer	0.00192	0.00524	CcSEcCtD
Methylergometrine—Rash—Erlotinib—pancreatic cancer	0.00191	0.00522	CcSEcCtD
Methylergometrine—Dermatitis—Erlotinib—pancreatic cancer	0.00191	0.00522	CcSEcCtD
Methylergometrine—Headache—Erlotinib—pancreatic cancer	0.0019	0.00519	CcSEcCtD
Methylergometrine—Paraesthesia—Gemcitabine—pancreatic cancer	0.00189	0.00517	CcSEcCtD
Methylergometrine—Dyspnoea—Gemcitabine—pancreatic cancer	0.00187	0.00513	CcSEcCtD
Methylergometrine—Paraesthesia—Fluorouracil—pancreatic cancer	0.00186	0.00508	CcSEcCtD
Methylergometrine—Dyspnoea—Fluorouracil—pancreatic cancer	0.00184	0.00504	CcSEcCtD
Methylergometrine—Nausea—Tamoxifen—pancreatic cancer	0.00182	0.00497	CcSEcCtD
Methylergometrine—Nausea—Erlotinib—pancreatic cancer	0.0018	0.00492	CcSEcCtD
Methylergometrine—Diarrhoea—Sunitinib—pancreatic cancer	0.00179	0.00491	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.00176	0.00483	CcSEcCtD
Methylergometrine—Muscle spasms—Docetaxel—pancreatic cancer	0.00176	0.00481	CcSEcCtD
Methylergometrine—Dizziness—Sunitinib—pancreatic cancer	0.00173	0.00474	CcSEcCtD
Methylergometrine—Angina pectoris—Epirubicin—pancreatic cancer	0.00172	0.00472	CcSEcCtD
Methylergometrine—Abdominal pain—Irinotecan—pancreatic cancer	0.00171	0.00467	CcSEcCtD
Methylergometrine—Vomiting—Sunitinib—pancreatic cancer	0.00166	0.00456	CcSEcCtD
Methylergometrine—Rash—Sunitinib—pancreatic cancer	0.00165	0.00452	CcSEcCtD
Methylergometrine—Dermatitis—Sunitinib—pancreatic cancer	0.00165	0.00452	CcSEcCtD
Methylergometrine—Headache—Sunitinib—pancreatic cancer	0.00164	0.00449	CcSEcCtD
Methylergometrine—Palpitations—Docetaxel—pancreatic cancer	0.00161	0.00442	CcSEcCtD
Methylergometrine—Angina pectoris—Doxorubicin—pancreatic cancer	0.00159	0.00436	CcSEcCtD
Methylergometrine—Convulsion—Docetaxel—pancreatic cancer	0.00158	0.00433	CcSEcCtD
Methylergometrine—Hypertension—Docetaxel—pancreatic cancer	0.00158	0.00432	CcSEcCtD
Methylergometrine—Chest pain—Docetaxel—pancreatic cancer	0.00156	0.00426	CcSEcCtD
Methylergometrine—Nausea—Sunitinib—pancreatic cancer	0.00156	0.00426	CcSEcCtD
Methylergometrine—Haematuria—Epirubicin—pancreatic cancer	0.0015	0.00412	CcSEcCtD
Methylergometrine—Anaphylactic shock—Docetaxel—pancreatic cancer	0.00149	0.00408	CcSEcCtD
Methylergometrine—Diarrhoea—Irinotecan—pancreatic cancer	0.00148	0.00404	CcSEcCtD
Methylergometrine—Nervous system disorder—Docetaxel—pancreatic cancer	0.00146	0.004	CcSEcCtD
Methylergometrine—Tachycardia—Docetaxel—pancreatic cancer	0.00146	0.00398	CcSEcCtD
Methylergometrine—Bradycardia—Epirubicin—pancreatic cancer	0.00144	0.00395	CcSEcCtD
Methylergometrine—Diarrhoea—Gemcitabine—pancreatic cancer	0.00144	0.00394	CcSEcCtD
Methylergometrine—Dizziness—Irinotecan—pancreatic cancer	0.00143	0.00391	CcSEcCtD
Methylergometrine—Diarrhoea—Fluorouracil—pancreatic cancer	0.00141	0.00387	CcSEcCtD
Methylergometrine—Hypotension—Docetaxel—pancreatic cancer	0.00139	0.00382	CcSEcCtD
Methylergometrine—Haematuria—Doxorubicin—pancreatic cancer	0.00139	0.00381	CcSEcCtD
Methylergometrine—Vomiting—Irinotecan—pancreatic cancer	0.00137	0.00376	CcSEcCtD
Methylergometrine—Dizziness—Fluorouracil—pancreatic cancer	0.00137	0.00374	CcSEcCtD
Methylergometrine—Rash—Irinotecan—pancreatic cancer	0.00136	0.00372	CcSEcCtD
Methylergometrine—Dermatitis—Irinotecan—pancreatic cancer	0.00136	0.00372	CcSEcCtD
Methylergometrine—Headache—Irinotecan—pancreatic cancer	0.00135	0.0037	CcSEcCtD
Methylergometrine—Paraesthesia—Docetaxel—pancreatic cancer	0.00134	0.00367	CcSEcCtD
Methylergometrine—Vomiting—Gemcitabine—pancreatic cancer	0.00134	0.00366	CcSEcCtD
Methylergometrine—Bradycardia—Doxorubicin—pancreatic cancer	0.00133	0.00365	CcSEcCtD
Methylergometrine—Dyspnoea—Docetaxel—pancreatic cancer	0.00133	0.00364	CcSEcCtD
Methylergometrine—Rash—Gemcitabine—pancreatic cancer	0.00132	0.00363	CcSEcCtD
Methylergometrine—Dermatitis—Gemcitabine—pancreatic cancer	0.00132	0.00362	CcSEcCtD
Methylergometrine—Tinnitus—Epirubicin—pancreatic cancer	0.00132	0.00361	CcSEcCtD
Methylergometrine—Headache—Gemcitabine—pancreatic cancer	0.00132	0.0036	CcSEcCtD
Methylergometrine—Cardiac disorder—Epirubicin—pancreatic cancer	0.00131	0.0036	CcSEcCtD
Methylergometrine—Vomiting—Fluorouracil—pancreatic cancer	0.00131	0.0036	CcSEcCtD
Methylergometrine—Rash—Fluorouracil—pancreatic cancer	0.0013	0.00357	CcSEcCtD
Methylergometrine—Dermatitis—Fluorouracil—pancreatic cancer	0.0013	0.00356	CcSEcCtD
Methylergometrine—Headache—Fluorouracil—pancreatic cancer	0.00129	0.00354	CcSEcCtD
Methylergometrine—Nausea—Irinotecan—pancreatic cancer	0.00128	0.00351	CcSEcCtD
Methylergometrine—Nausea—Gemcitabine—pancreatic cancer	0.00125	0.00342	CcSEcCtD
Methylergometrine—Nausea—Fluorouracil—pancreatic cancer	0.00123	0.00336	CcSEcCtD
Methylergometrine—Tinnitus—Doxorubicin—pancreatic cancer	0.00122	0.00334	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.00122	0.00334	CcSEcCtD
Methylergometrine—Cardiac disorder—Doxorubicin—pancreatic cancer	0.00122	0.00333	CcSEcCtD
Methylergometrine—Muscle spasms—Epirubicin—pancreatic cancer	0.00118	0.00324	CcSEcCtD
Methylergometrine—Abdominal pain—Docetaxel—pancreatic cancer	0.00118	0.00323	CcSEcCtD
Methylergometrine—Muscle spasms—Doxorubicin—pancreatic cancer	0.0011	0.003	CcSEcCtD
Methylergometrine—Palpitations—Epirubicin—pancreatic cancer	0.00109	0.00298	CcSEcCtD
Methylergometrine—Convulsion—Epirubicin—pancreatic cancer	0.00107	0.00292	CcSEcCtD
Methylergometrine—Hypertension—Epirubicin—pancreatic cancer	0.00106	0.00291	CcSEcCtD
Methylergometrine—Chest pain—Epirubicin—pancreatic cancer	0.00105	0.00287	CcSEcCtD
Methylergometrine—Diarrhoea—Docetaxel—pancreatic cancer	0.00102	0.00279	CcSEcCtD
Methylergometrine—Palpitations—Doxorubicin—pancreatic cancer	0.00101	0.00276	CcSEcCtD
Methylergometrine—Anaphylactic shock—Epirubicin—pancreatic cancer	0.00101	0.00275	CcSEcCtD
Methylergometrine—Convulsion—Doxorubicin—pancreatic cancer	0.000988	0.00271	CcSEcCtD
Methylergometrine—Nervous system disorder—Epirubicin—pancreatic cancer	0.000986	0.0027	CcSEcCtD
Methylergometrine—Dizziness—Docetaxel—pancreatic cancer	0.000986	0.0027	CcSEcCtD
Methylergometrine—Hypertension—Doxorubicin—pancreatic cancer	0.000984	0.0027	CcSEcCtD
Methylergometrine—Tachycardia—Epirubicin—pancreatic cancer	0.000982	0.00269	CcSEcCtD
Methylergometrine—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000972	0.00266	CcSEcCtD
Methylergometrine—Chest pain—Doxorubicin—pancreatic cancer	0.000971	0.00266	CcSEcCtD
Methylergometrine—Vomiting—Docetaxel—pancreatic cancer	0.000948	0.0026	CcSEcCtD
Methylergometrine—Rash—Docetaxel—pancreatic cancer	0.00094	0.00257	CcSEcCtD
Methylergometrine—Hypotension—Epirubicin—pancreatic cancer	0.00094	0.00257	CcSEcCtD
Methylergometrine—Dermatitis—Docetaxel—pancreatic cancer	0.000939	0.00257	CcSEcCtD
Methylergometrine—Headache—Docetaxel—pancreatic cancer	0.000934	0.00256	CcSEcCtD
Methylergometrine—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000931	0.00255	CcSEcCtD
Methylergometrine—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000913	0.0025	CcSEcCtD
Methylergometrine—Tachycardia—Doxorubicin—pancreatic cancer	0.000908	0.00249	CcSEcCtD
Methylergometrine—Paraesthesia—Epirubicin—pancreatic cancer	0.000903	0.00247	CcSEcCtD
Methylergometrine—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.0009	0.00246	CcSEcCtD
Methylergometrine—Dyspnoea—Epirubicin—pancreatic cancer	0.000897	0.00246	CcSEcCtD
Methylergometrine—Nausea—Docetaxel—pancreatic cancer	0.000886	0.00243	CcSEcCtD
Methylergometrine—Hypotension—Doxorubicin—pancreatic cancer	0.00087	0.00238	CcSEcCtD
Methylergometrine—Paraesthesia—Doxorubicin—pancreatic cancer	0.000836	0.00229	CcSEcCtD
Methylergometrine—Dyspnoea—Doxorubicin—pancreatic cancer	0.00083	0.00227	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000822	0.00225	CcSEcCtD
Methylergometrine—Abdominal pain—Epirubicin—pancreatic cancer	0.000795	0.00218	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000761	0.00208	CcSEcCtD
Methylergometrine—Abdominal pain—Doxorubicin—pancreatic cancer	0.000736	0.00201	CcSEcCtD
Methylergometrine—Diarrhoea—Epirubicin—pancreatic cancer	0.000688	0.00188	CcSEcCtD
Methylergometrine—Dizziness—Epirubicin—pancreatic cancer	0.000665	0.00182	CcSEcCtD
Methylergometrine—Vomiting—Epirubicin—pancreatic cancer	0.000639	0.00175	CcSEcCtD
Methylergometrine—Diarrhoea—Doxorubicin—pancreatic cancer	0.000637	0.00174	CcSEcCtD
Methylergometrine—Rash—Epirubicin—pancreatic cancer	0.000634	0.00174	CcSEcCtD
Methylergometrine—Dermatitis—Epirubicin—pancreatic cancer	0.000634	0.00173	CcSEcCtD
Methylergometrine—Headache—Epirubicin—pancreatic cancer	0.00063	0.00173	CcSEcCtD
Methylergometrine—Dizziness—Doxorubicin—pancreatic cancer	0.000615	0.00169	CcSEcCtD
Methylergometrine—Nausea—Epirubicin—pancreatic cancer	0.000597	0.00164	CcSEcCtD
Methylergometrine—Vomiting—Doxorubicin—pancreatic cancer	0.000592	0.00162	CcSEcCtD
Methylergometrine—Rash—Doxorubicin—pancreatic cancer	0.000587	0.00161	CcSEcCtD
Methylergometrine—Dermatitis—Doxorubicin—pancreatic cancer	0.000586	0.00161	CcSEcCtD
Methylergometrine—Headache—Doxorubicin—pancreatic cancer	0.000583	0.0016	CcSEcCtD
Methylergometrine—Nausea—Doxorubicin—pancreatic cancer	0.000553	0.00151	CcSEcCtD
Methylergometrine—HTR2C—Signaling Pathways—GCG—pancreatic cancer	0.000129	0.000203	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—HES1—pancreatic cancer	0.000129	0.000203	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000128	0.000202	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—PIK3CA—pancreatic cancer	0.000128	0.000201	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—SST—pancreatic cancer	0.000126	0.000198	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000126	0.000198	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—SMAD4—pancreatic cancer	0.000124	0.000196	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000124	0.000195	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—PIK3CB—pancreatic cancer	0.000124	0.000195	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—PIK3CB—pancreatic cancer	0.000123	0.000194	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—AGTR1—pancreatic cancer	0.000123	0.000194	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—JAG1—pancreatic cancer	0.000123	0.000194	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—CXCL8—pancreatic cancer	0.000123	0.000194	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PRSS1—pancreatic cancer	0.000123	0.000193	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—NOTCH3—pancreatic cancer	0.000123	0.000193	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—STK11—pancreatic cancer	0.000121	0.000191	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—HES1—pancreatic cancer	0.000121	0.000191	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—PIK3CA—pancreatic cancer	0.00012	0.00019	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—CXCL8—pancreatic cancer	0.000119	0.000187	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—CXCL8—pancreatic cancer	0.000118	0.000187	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—HRAS—pancreatic cancer	0.000118	0.000186	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—PIK3CB—pancreatic cancer	0.000117	0.000184	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—PIK3CB—pancreatic cancer	0.000116	0.000183	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CNR1—pancreatic cancer	0.000116	0.000183	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR downstream signaling—AKT1—pancreatic cancer	0.000115	0.000181	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—PIK3CD—pancreatic cancer	0.000114	0.00018	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—CASP3—pancreatic cancer	0.000114	0.000179	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—TERT—pancreatic cancer	0.000113	0.000178	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000113	0.000177	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—CXCL8—pancreatic cancer	0.000112	0.000177	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—GCG—pancreatic cancer	0.000112	0.000177	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—CXCL8—pancreatic cancer	0.000112	0.000176	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—HRAS—pancreatic cancer	0.000111	0.000176	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—CCND1—pancreatic cancer	0.000111	0.000175	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—CTNNB1—pancreatic cancer	0.00011	0.000173	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000109	0.000172	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000109	0.000172	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR downstream signaling—AKT1—pancreatic cancer	0.000108	0.000171	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—HIF1A—pancreatic cancer	0.000108	0.00017	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—MMP9—pancreatic cancer	0.000108	0.000169	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—TSC2—pancreatic cancer	0.000108	0.000169	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—CASP3—pancreatic cancer	0.000107	0.000169	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—AGTR1—pancreatic cancer	0.000107	0.000168	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—PTEN—pancreatic cancer	0.000107	0.000168	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ARG2—pancreatic cancer	0.000106	0.000168	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—TERT—pancreatic cancer	0.000106	0.000167	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—SMAD4—pancreatic cancer	0.000106	0.000167	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—STK11—pancreatic cancer	0.000105	0.000166	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—APOE—pancreatic cancer	0.000105	0.000166	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—CXCL8—pancreatic cancer	0.000105	0.000166	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—CCND1—pancreatic cancer	0.000105	0.000165	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—AKT1—pancreatic cancer	0.000104	0.000164	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—HES1—pancreatic cancer	0.000104	0.000164	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—CTNNB1—pancreatic cancer	0.000103	0.000163	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—KDR—pancreatic cancer	0.000103	0.000162	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—HIF1A—pancreatic cancer	0.000102	0.00016	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—MMP9—pancreatic cancer	0.000101	0.00016	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—TSC2—pancreatic cancer	0.000101	0.00016	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—PTEN—pancreatic cancer	0.000101	0.000159	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—PIK3CB—pancreatic cancer	9.94e-05	0.000157	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—APOE—pancreatic cancer	9.93e-05	0.000156	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—SRC—pancreatic cancer	9.92e-05	0.000156	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—PIK3CD—pancreatic cancer	9.9e-05	0.000156	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—AKT1—pancreatic cancer	9.84e-05	0.000155	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—NFKBIA—pancreatic cancer	9.81e-05	0.000155	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—KDR—pancreatic cancer	9.72e-05	0.000153	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—NOTCH1—pancreatic cancer	9.71e-05	0.000153	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—VEGFA—pancreatic cancer	9.66e-05	0.000152	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—STAT3—pancreatic cancer	9.56e-05	0.000151	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—CXCL8—pancreatic cancer	9.55e-05	0.00015	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—NRAS—pancreatic cancer	9.54e-05	0.00015	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—PIK3CB—pancreatic cancer	9.51e-05	0.00015	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PIK3CG—pancreatic cancer	9.5e-05	0.00015	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—NRAS—pancreatic cancer	9.5e-05	0.00015	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—EGF—pancreatic cancer	9.39e-05	0.000148	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—SRC—pancreatic cancer	9.35e-05	0.000147	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—TYMP—pancreatic cancer	9.3e-05	0.000147	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—NFKBIA—pancreatic cancer	9.25e-05	0.000146	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—SMAD4—pancreatic cancer	9.23e-05	0.000145	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—NOTCH1—pancreatic cancer	9.16e-05	0.000144	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—CXCL8—pancreatic cancer	9.13e-05	0.000144	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—VEGFA—pancreatic cancer	9.11e-05	0.000144	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—TERT—pancreatic cancer	9.1e-05	0.000143	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—STAT3—pancreatic cancer	9.02e-05	0.000142	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—HES1—pancreatic cancer	9.01e-05	0.000142	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—NRAS—pancreatic cancer	9e-05	0.000142	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PIK3CG—pancreatic cancer	8.96e-05	0.000141	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—NRAS—pancreatic cancer	8.96e-05	0.000141	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—MYC—pancreatic cancer	8.89e-05	0.00014	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—TGFB1—pancreatic cancer	8.86e-05	0.00014	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—EGF—pancreatic cancer	8.85e-05	0.000139	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—HIF1A—pancreatic cancer	8.7e-05	0.000137	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—EGFR—pancreatic cancer	8.69e-05	0.000137	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—TSC2—pancreatic cancer	8.68e-05	0.000137	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—EGFR—pancreatic cancer	8.65e-05	0.000136	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—PIK3CB—pancreatic cancer	8.63e-05	0.000136	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—APOE—pancreatic cancer	8.49e-05	0.000134	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—MYC—pancreatic cancer	8.38e-05	0.000132	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—TGFB1—pancreatic cancer	8.36e-05	0.000132	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PIK3CD—pancreatic cancer	8.35e-05	0.000132	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—KDR—pancreatic cancer	8.32e-05	0.000131	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—CXCL8—pancreatic cancer	8.29e-05	0.000131	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.27e-05	0.00013	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—KRAS—pancreatic cancer	8.21e-05	0.000129	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—EGFR—pancreatic cancer	8.2e-05	0.000129	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—KRAS—pancreatic cancer	8.18e-05	0.000129	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—EGFR—pancreatic cancer	8.16e-05	0.000129	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—NFKBIA—pancreatic cancer	7.91e-05	0.000125	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—TERT—pancreatic cancer	7.9e-05	0.000124	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PIK3CD—pancreatic cancer	7.87e-05	0.000124	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—NOTCH1—pancreatic cancer	7.84e-05	0.000123	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—PIK3CA—pancreatic cancer	7.8e-05	0.000123	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—KRAS—pancreatic cancer	7.75e-05	0.000122	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—KRAS—pancreatic cancer	7.71e-05	0.000121	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PIK3CG—pancreatic cancer	7.66e-05	0.000121	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—NRAS—pancreatic cancer	7.66e-05	0.000121	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—EGF—pancreatic cancer	7.57e-05	0.000119	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—HIF1A—pancreatic cancer	7.55e-05	0.000119	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—PIK3CA—pancreatic cancer	7.54e-05	0.000119	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—TSC2—pancreatic cancer	7.53e-05	0.000119	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—PIK3CA—pancreatic cancer	7.51e-05	0.000118	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GLP1R—pancreatic cancer	7.5e-05	0.000118	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—DPYD—pancreatic cancer	7.38e-05	0.000116	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—APOE—pancreatic cancer	7.37e-05	0.000116	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—TP53—pancreatic cancer	7.3e-05	0.000115	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PIK3CB—pancreatic cancer	7.28e-05	0.000115	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—KDR—pancreatic cancer	7.22e-05	0.000114	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—PIK3CA—pancreatic cancer	7.12e-05	0.000112	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—PIK3CA—pancreatic cancer	7.08e-05	0.000112	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	7e-05	0.00011	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CXCL8—pancreatic cancer	6.99e-05	0.00011	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—EGFR—pancreatic cancer	6.98e-05	0.00011	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—HRAS—pancreatic cancer	6.98e-05	0.00011	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—HRAS—pancreatic cancer	6.95e-05	0.000109	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—TP53—pancreatic cancer	6.88e-05	0.000108	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—NFKBIA—pancreatic cancer	6.87e-05	0.000108	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PIK3CB—pancreatic cancer	6.86e-05	0.000108	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—NOTCH1—pancreatic cancer	6.8e-05	0.000107	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—AKT1—pancreatic cancer	6.76e-05	0.000106	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PIK3CD—pancreatic cancer	6.74e-05	0.000106	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CASP3—pancreatic cancer	6.69e-05	0.000105	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.67e-05	0.000105	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PIK3CG—pancreatic cancer	6.65e-05	0.000105	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—NRAS—pancreatic cancer	6.65e-05	0.000105	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CXCL8—pancreatic cancer	6.6e-05	0.000104	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—KRAS—pancreatic cancer	6.6e-05	0.000104	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—HRAS—pancreatic cancer	6.58e-05	0.000104	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—EGF—pancreatic cancer	6.58e-05	0.000104	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—HRAS—pancreatic cancer	6.55e-05	0.000103	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CCND1—pancreatic cancer	6.52e-05	0.000103	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CTNNB1—pancreatic cancer	6.45e-05	0.000102	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—AKT1—pancreatic cancer	6.37e-05	0.0001	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MMP9—pancreatic cancer	6.33e-05	9.97e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CASP3—pancreatic cancer	6.31e-05	9.95e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PTEN—pancreatic cancer	6.29e-05	9.91e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—AKT1—pancreatic cancer	6.16e-05	9.71e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CCND1—pancreatic cancer	6.15e-05	9.68e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—AKT1—pancreatic cancer	6.14e-05	9.67e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CTNNB1—pancreatic cancer	6.09e-05	9.59e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—EGFR—pancreatic cancer	6.06e-05	9.55e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—PIK3CA—pancreatic cancer	6.06e-05	9.55e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MMP9—pancreatic cancer	5.97e-05	9.4e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PTEN—pancreatic cancer	5.93e-05	9.34e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PIK3CB—pancreatic cancer	5.87e-05	9.25e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PIK3CD—pancreatic cancer	5.85e-05	9.22e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—SRC—pancreatic cancer	5.83e-05	9.19e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—AKT1—pancreatic cancer	5.81e-05	9.16e-05	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	5.79e-05	9.13e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—AKT1—pancreatic cancer	5.79e-05	9.12e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—KRAS—pancreatic cancer	5.73e-05	9.02e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—VEGFA—pancreatic cancer	5.68e-05	8.95e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CXCL8—pancreatic cancer	5.64e-05	8.89e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—STAT3—pancreatic cancer	5.62e-05	8.86e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—NRAS—pancreatic cancer	5.61e-05	8.84e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—HRAS—pancreatic cancer	5.61e-05	8.83e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—SRC—pancreatic cancer	5.5e-05	8.66e-05	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—AKT1—pancreatic cancer	5.45e-05	8.59e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CD44—pancreatic cancer	5.42e-05	8.54e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CASP3—pancreatic cancer	5.4e-05	8.51e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—VEGFA—pancreatic cancer	5.36e-05	8.44e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—STAT3—pancreatic cancer	5.3e-05	8.36e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—NRAS—pancreatic cancer	5.29e-05	8.34e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—PIK3CA—pancreatic cancer	5.26e-05	8.29e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CCND1—pancreatic cancer	5.26e-05	8.28e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MYC—pancreatic cancer	5.23e-05	8.23e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—TGFB1—pancreatic cancer	5.21e-05	8.21e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CTNNB1—pancreatic cancer	5.21e-05	8.2e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GCG—pancreatic cancer	5.2e-05	8.19e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—EGFR—pancreatic cancer	5.11e-05	8.05e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MMP9—pancreatic cancer	5.1e-05	8.04e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PIK3CB—pancreatic cancer	5.1e-05	8.03e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PTEN—pancreatic cancer	5.07e-05	7.99e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	4.95e-05	7.8e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MYC—pancreatic cancer	4.93e-05	7.76e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—TGFB1—pancreatic cancer	4.92e-05	7.75e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	4.9e-05	7.72e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—STK11—pancreatic cancer	4.89e-05	7.7e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	4.87e-05	7.67e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—KRAS—pancreatic cancer	4.83e-05	7.61e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—EGFR—pancreatic cancer	4.82e-05	7.59e-05	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	4.73e-05	7.46e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—SRC—pancreatic cancer	4.71e-05	7.41e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	4.69e-05	7.39e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	4.58e-05	7.22e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	4.57e-05	7.19e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—KRAS—pancreatic cancer	4.55e-05	7.17e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	4.54e-05	7.15e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	4.53e-05	7.13e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	4.52e-05	7.12e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PIK3CA—pancreatic cancer	4.44e-05	6.99e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	4.43e-05	6.98e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	4.41e-05	6.94e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	4.3e-05	6.77e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—TP53—pancreatic cancer	4.29e-05	6.76e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MYC—pancreatic cancer	4.22e-05	6.64e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	4.21e-05	6.63e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—TYMS—pancreatic cancer	4.2e-05	6.62e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PIK3CA—pancreatic cancer	4.18e-05	6.59e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	4.12e-05	6.5e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—HRAS—pancreatic cancer	4.11e-05	6.47e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—SRC—pancreatic cancer	4.09e-05	6.44e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—TP53—pancreatic cancer	4.05e-05	6.38e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	3.98e-05	6.27e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	3.94e-05	6.21e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	3.93e-05	6.19e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	3.9e-05	6.14e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—HRAS—pancreatic cancer	3.87e-05	6.1e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MYC—pancreatic cancer	3.66e-05	5.77e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	3.65e-05	5.75e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—AKT1—pancreatic cancer	3.62e-05	5.71e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	3.58e-05	5.64e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	3.58e-05	5.64e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—TP53—pancreatic cancer	3.46e-05	5.46e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—AKT1—pancreatic cancer	3.42e-05	5.38e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—APOE—pancreatic cancer	3.42e-05	5.38e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	3.38e-05	5.33e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	3.31e-05	5.22e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	3.11e-05	4.9e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	3.08e-05	4.86e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—TP53—pancreatic cancer	3.01e-05	4.74e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PPARG—pancreatic cancer	2.98e-05	4.69e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	2.92e-05	4.61e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	2.88e-05	4.53e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	2.71e-05	4.27e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	2.54e-05	4e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.36e-05	3.72e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.34e-05	3.69e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PTEN—pancreatic cancer	2.04e-05	3.22e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.44e-05	2.27e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.18e-05	1.85e-05	CbGpPWpGaD
